SEARCH:   Advanced

Blood, 1 November 2006, Vol. 108, No. 9, pp. 3216-3222. Prepublished online as a Blood First Edition Paper on July 11, 2006; DOI 10.1182/blood-2006-04-017780. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2006-04-017780v1 108/9/3216    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Blazar, B. R. Articles by Ferrara, J. L. M. Search for Related Content PubMed PubMed Citation Articles by Blazar, B. R. Articles by Ferrara, J. L. M. Related Collections Neoplasia Transplantation Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSPLANTATION Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT) Bruce R. Blazar, Daniel J. Weisdorf, Todd DeFor, Anne Goldman, Thomas Braun, Samuel Silver, and James L. M. Ferrara From the Cancer Center, University of Minnesota, Minneapolis; the Department of Pediatrics, Division of Hematology/Oncology and Blood and Marrow Transplantation, University of Minnesota, Minneapolis; the Department of Medicine, Division of Hematology/Oncology and Blood and Marrow Transplantation, University of Minnesota, Minneapolis; the Biostatistical Support Group, University of Minnesota, Minneapolis; the School of Public Health, Department of Biostatistics, University of Michigan, Ann Arbor; the Divisions of Hematology/Oncology, Department of Pediatrics, University of Michigan Medical School, Ann Arbor; the Divisions of Hematology/Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor; and the University of Michigan Comprehensive Cancer Center, Ann Arbor. Palifermin, a recombinant human keratinocyte growth factor, was tested for potential benefits on acute graft-versus-host disease (GVHD) and hematopoietic recovery in allogeneic hematopoietic stem cell transplantation (HSCT) recipients. This randomized, double-blind, placebo-controlled, dose-escalation study assessed the safety and tolerability of palifermin (n = 69) as compared with placebo (n = 31) in patients conditioned with cyclophosphamide and fractionated total-body irradiation (Cy/TBI) or busulfan and cyclophosphamide (Bu/Cy) and given methotrexate along with a calcineurin inhibitor (cyclosporine A, tacrolimus) for GVHD prophylaxis. All patients received 3 doses before conditioning and either 3 (cohort 1), 6 (cohort 2), or 9 (cohort 3) doses after HSCT. Palifermin doses were 40 µg/kg per day (cohort 1 only) or 60 µg/kg per day (all cohorts). Six patients (placebo = 2, palifermin = 4) experienced a total of 11 dose-limiting toxicities (most often skin, respiratory, or oral mucositis). The most common adverse events included edema, infection, skin pain, or rash. Times to neutrophil and platelet engraftment were similar. No significant differences in acute GVHD incidence or severity, survival, or day 100 relapse rates were observed between groups. Palifermin was associated with reduced incidence and mean severity of mucositis in patients conditioned with Cy/TBI but not Bu/Cy. We conclude that palifermin was generally safe in allogeneic HSCTs but had no significant effect on engraftment, acute GVHD, or survival in this trial. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J. W. Han, S. Y. Kwon, S. C. Won, Y. J. Shin, J. H. Ko, and C. J. Lyu Comprehensive clinical follow-up of late effects in childhood cancer survivors shows the need for early and well-timed intervention Ann. Onc., July 1, 2009; 20(7): 1170 - 1177. [Abstract] [Full Text] [PDF] E. Clave, M. Busson, C. Douay, R. Peffault de Latour, J. Berrou, C. Rabian, M. Carmagnat, V. Rocha, D. Charron, G. Socie, et al. Acute graft-versus-host disease transiently impairs thymic output in young patients after allogeneic hematopoietic stem cell transplantation Blood, June 18, 2009; 113(25): 6477 - 6484. [Abstract] [Full Text] [PDF] M. L. Hensley, K. L. Hagerty, T. Kewalramani, D. M. Green, N. J. Meropol, T. H. Wasserman, G. I. Cohen, B. Emami, W. J. Gradishar, R. B. Mitchell, et al. American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiation Therapy Protectants J. Clin. Oncol., January 1, 2009; 27(1): 127 - 145. [Abstract] [Full Text] [PDF] Y. Zhang, E. Hexner, D. Frank, and S. G. Emerson CD4+ T Cells Generated De Novo from Donor Hemopoietic Stem Cells Mediate the Evolution from Acute to Chronic Graft-versus-Host Disease J. Immunol., September 1, 2007; 179(5): 3305 - 3314. [Abstract] [Full Text] [PDF] S. W. Rossi, L. T. Jeker, T. Ueno, S. Kuse, M. P. Keller, S. Zuklys, A. V. Gudkov, Y. Takahama, W. Krenger, B. R. Blazar, et al. Keratinocyte growth factor (KGF) enhances postnatal T-cell development via enhancements in proliferation and function of thymic epithelial cells Blood, May 1, 2007; 109(9): 3803 - 3811. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020